Department of Obstetrics and Gynecology, Phramongkutklao Hospital, Bangkok, ThailandFulltext PDF
Objective: The main objective of this study was to evaluate the Overall Survival (OS) outcome of Thai patients treated for stage IVB, persistent, or recurrent adenocarcinoma of the uterine cervix in the Phramongkutklao Hospital with standard chemotherapies. Progression Free Survival (PFS), Overall Response Rate (ORR) and prognostic factors were calculated.Methods: A retrospective chart study was conducted. All patients with stage IVB, persistent, or recurrent disease, treated between July 1993 and June 2013 were included. Patients’ baseline characteristics were collected. OS and PFS were calculated by the Kaplan-Meier method.Results: Forty patients were enrolled with a mean age of 51.4 years. The chemotherapy regimens were cisplatin plus ifosfamide, cisplatin plus irinotecan, platinum-based chemotherapy plus paclitaxel, and 4 other regimens. The median OS of all 40 patients were 7.8 months. The median OS were 6.7, 11.2, 5.5, and 9.3 months for cisplatin/ifosfamide, cisplatin/irinotecan, platinum/paclitaxel, and other regimens group, respectively. Most adverse effects were manageable and hematologic toxicity was the most common. A univariate analysis of various prognostic factors, (age >60 years, hemoglobin level <12 g/dl, relapse inside the irradiation field, and time to relapse within 6 months), was non-contributory.Conclusion: Cisplatin plus irinotecan achieved the highest response rate and OS without statistical significance compared to the other regimens. However, the observed trend merits confirmation in a larger Thai population.
Adenocarcinoma, Metastatic cervical cancer, Cancer recurrence, Chemotherapy
Rittiluechai K. Survival Outcomes in Thai Patients with Stage IVB, Persistent or Recurrent Adenocarcinoma of the Uterine Cervix Treated with PlatinumBased Combination Chemotherapy. Clin Oncol. 2018; 3: 1535.